The American Foundation for Suicide Prevention in New York appointed David Dodd chairman.
Atugen AG, of Berlin, appointed Cy Stein to its scientific advisory board.
InKine Pharmaceutical Co. Inc., of Blue Bell, Pa., appointed John Cullen senior vice president and general counsel. The company also said that Leonard Jacob was appointed to the Colon Cancer Alliance's board.
IsoTis OrthoBiologics, of Lausanne, Switzerland, appointed Robert Morocco chief financial officer.
Liponomics Technologies Inc., of West Sacramento, Calif., appointed Macdonald Morris chief technology officer and vice president of bioinformatics.
MedSynergies Inc., of Irving, Texas, appointed Bill Murray chief financial officer.
Memory Pharmaceuticals Corp., of Montvale, N.J., said its CEO Tony Scullion was appointed to the board of the Biotechnology Council of New Jersey.
Mymetics Corp., of Nyon, Switzerland, appointed Stanley Plotkin to its board.
NeurogesX, of San Carlos, Calif., appointed Karen Harder senior vice president, regulatory and technical operations.
Neurotech, of Lincoln, R.I., appointed Al Reaves vice president of clinical development.
The New York Biotechnology Association in New York appointed Jack Huttner chairman.
Pepgen Corp., of Alameda, Calif., appointed Gary Shangold to its board.
Pharmacopeia Drug Discovery Inc., of Princeton, N.J., appointed David Floyd executive vice president of discovery and chief scientific officer.
Pharming Group NV, of Leiden, the Netherlands, appointed Ron van Amsterdam director clinical development, and Lilian Tijburg director quality assurance.
Pharsight Corp., of Mountain View, Calif., appointed Jonathan Kuwabara-Wagg senior scientist in the drug development consulting division.
The Pittsburgh Life Sciences Greenhouse appointed James Jordan executive-in-residence.
Reliant Pharmaceuticals Inc., of Liberty Corner, N.J., appointed Joseph Zakrzewski chief operating officer and Robert Ferguson chief financial officer.
SciClone Pharmaceuticals Inc., of San Mateo, Calif., appointed Dean Woodman chairman.
Sirna Therapeutics Inc., of Boulder, Colo., appointed Rebecca Galler Robison senior director of corporate strategy.
Targanta Therapeutics Inc., of Montreal, appointed Thomas Parr chief scientific officer.
Threshold Pharmaceuticals, of Redwood City, Calif., appointed Alan Colowick chief medical officer.
U3 Pharma AG, of Martinsried, Germany, appointed Josefin-Beate Holz vice president, drug development.
Vicuron Pharmaceuticals Inc., of King of Prussia, Pa., promoted David Krause to executive vice president and chief medical officer.
Vitae Pharmaceuticals Inc., of Fort Washington, Pa., appointed Alex Howarth chief business officer.
Xenogen Corp., of Alameda, Calif., appointed Gregory Schiffman to its board.